FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

QuVa Pharma oxyTOCIN 30 Units/500 mL Recall

oxyTOCIN 30 Units/500 mL (0

QuVa Pharma, Inc. · Bloomsbury, NJ

Risk level
Class III
Reported by FDA
Oct 5, 2022
Recall ID
D-1544-2022
Check your lot numberHow we source this data

Summary

QuVa Pharma recalled oxyTOCIN 30 Units/500 mL starting Sep 20, 2022. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-1544-2022 on Oct 5, 2022. Reason: Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL). Status: Terminated.

Why it was recalled

Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).

Product description

oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injection for IV Use, High Alert, This is a Compounded Product for Institutional or Office Use Only, Not for Resale, QuVa PHARMA 519 Route 173, Bloomsbury, NJ 08804, Total volume: 500 mL bag, NDC: 70092-1068-07.

Lot numbers, UPCs & expiration codes

Lot 30027403, BUD 11/14/2022

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1544-2022
Classification
Class III
Status
Terminated
Recall initiated
Sep 20, 2022
FDA report date
Oct 5, 2022
Quantity
1994 bags
Recall type
Voluntary: Firm initiated
Recalling firm
QuVa Pharma, Inc.

Original FDA data

Every field from FDA enforcement report D-1544-2022, exactly as published.

Show all FDA fields
City
Bloomsbury
State
NJ
Status
Terminated
Country
United States
Event ID
90898
Address
519 State Route 173
Code information
Lot 30027403, BUD 11/14/2022
Postal code
08804-4047
Report date
Oct 5, 2022
Product type
Drugs
Recall number
D-1544-2022
Classification
Class III
Recalling firm
QuVa Pharma, Inc.
Product quantity
1994 bags
Termination date
Feb 8, 2023
Reason for recall
Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).
Voluntary / mandated
Voluntary: Firm initiated
Product description
oxyTOCIN 30 Units/500 mL (0.06 Units/mL) added to 0.9% Sodium Chloride, Injection for IV Use, High Alert, This is a Compounded Product for Institutional or Office Use Only, Not for Resale, QuVa PHARMA 519 Route 173, Bloomsbury, NJ 08804, Total volume: 500 mL bag, NDC: 70092-1068-07.
Distribution pattern
Nationwide in the USA
Recall initiation date
Sep 20, 2022
Initial firm notification
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Center classification date
Sep 26, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1544-2022, published Oct 5, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls